{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T21:46:33Z","timestamp":1777067193111,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inhaled beta-2 adrenoceptor agonists (i\u03b22A) are routinely used as bronchodilators in the treatment of asthma. However, their cardiac effects in athletes are scarcely examined. Thus, the aim of this study was to evaluate the effects of i\u03b22A on left ventricular (LV) systolic function (SF) by echocardiography in healthy, non-asthmatic female and male endurance athletes. A randomized, double-blinded, placebo-controlled, balanced, 4-way complete block cross-over study was conducted. Twenty-four healthy athletes (12f\/12m: 22.9\u2009\u00b1\u20092.7\/24.4\u2009\u00b1\u20094.6 years) randomly completed 4 study arms (placebo; salbutamol; formoterol; formoterol\u2009+\u2009salbutamol). After inhalation of the study medication, the participants performed a 10-min time trial (TT) on a bicycle ergometer. After each TT an echocardiography was performed to determine LVSF. Blood samples were collected pre, post, 3\u00a0h and 24\u00a0h post TT. In females, total serum concentrations for salbutamol and formoterol were higher. LV ejection fraction (LVEF) and LV global longitudinal strain (LVendoGLS) showed a treatment effect for the whole study group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and a sex effect on LVEF (<jats:italic>p<\/jats:italic>\u2009=\u20090.0085). In women, there was a significant treatment effect for all medication arms (at least <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.01) both on LVEF and LVendoGLS. In men only formoterol and formoterol\u2009+\u2009salbutamol displayed a treatment effect on LVEF (<jats:italic>p<\/jats:italic>\u2009=\u20090.0427, <jats:italic>p<\/jats:italic>\u2009=\u20090.0330; respectively), whereas on LVendoGLS only formoterol\u2009+\u2009salbutamol was significant (<jats:italic>p<\/jats:italic>\u2009=\u20090.0473). The i\u03b22A significantly influenced LVSF after an acute bout of exercise in healthy endurance athletes. These effects were even more pronounced when combining both i\u03b22A that supports a dose-dependent effect on cardiac function. Moreover, female athletes had higher serum concentrations of \u03b22 agonists and stronger effects on LVSF compared to male athletes. This is mainly explained by differences in body weight and related plasma volume and may indicate a potential risk when increasing dose above the tested concentrations. <\/jats:p><jats:p><jats:bold>Trial registration:<\/jats:bold> At the European Union Drug Regulating Authorities Clinical Trials (Eudra CT) with the number 201,500,559,819 (registered prospectively on 09\/12\/2015) and at the German register for clinical studies (DRKS number 00010574 registered retrospectively on 16\/11\/2021).<\/jats:p>","DOI":"10.1038\/s41598-024-74095-z","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:02:09Z","timestamp":1728388929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Left ventricular systolic function after inhalation of beta-2 agonists in healthy athletes"],"prefix":"10.1038","volume":"14","author":[{"given":"H.","family":"Persch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Bizjak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Takabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Schober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Winkert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dreyhaupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. C.","family":"Harps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Diel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. K.","family":"Parr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Z\u00fcgel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Steinacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"74095_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/bjsports-2011-090814","volume":"46","author":"KD Fitch","year":"2012","unstructured":"Fitch, K. D. An overview of asthma and airway hyper-responsiveness in olympic athletes. Br. J. Sports Med. 46, 413\u2013416 (2012).","journal-title":"Br. J. Sports Med."},{"key":"74095_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/bjsports-2021-104601","volume":"56","author":"OJ Price","year":"2022","unstructured":"Price, O. J. et al. Prevalence of lower airway dysfunction in athletes: a systematic review and meta-analysis by a subgroup of the IOC consensus group on \u2018acute respiratory illness in the athlete\u2019. Br. J. Sports Med. 56, 213\u2013222 (2022).","journal-title":"Br. J. Sports Med."},{"key":"74095_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/s-0037-1606215","volume":"39","author":"A Cote","year":"2018","unstructured":"Cote, A., Turmel, J. & Boulet, L. P. Exercise and asthma. Semin. Respir. Crit. Care Med. 39, 19\u201328 (2018).","journal-title":"Semin Respir Crit. Care Med."},{"key":"74095_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/02770903.2020.1728769","volume":"58","author":"T Irewall","year":"2021","unstructured":"Irewall, T., Soderstrom, L., Lindberg, A. & Stenfors, N. High incidence rate of asthma among elite endurance athletes: a prospective 4-year survey. J. Asthma.  58, 735\u2013741 (2021).","journal-title":"J. Asthma"},{"key":"74095_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41533-023-00330-1","volume":"33","author":"ML Levy","year":"2023","unstructured":"Levy, M. L. et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim. Care Respir. Med. 33, 7 (2023).","journal-title":"NPJ Prim. Care Respir Med."},{"key":"74095_CR6","unstructured":"Asthma, G. I. F. Global strategy for asthma management and prevention. 2024 GINA Report (update 22.05.2024) (2024)."},{"key":"74095_CR7","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jaip.2024.01.011","volume":"12","author":"JG Krings","year":"2024","unstructured":"Krings, J. G. & Beasley, R. The role of ICS-containing rescue therapy versus SABA alone in asthma management today. J. Allergy Clin. Immunol. Pract. 12, 870\u2013879 (2024).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"74095_CR8","doi-asserted-by":"crossref","unstructured":"Hostrup, M. et al., Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training: a randomised controlled trial. ERJ Open Res.  9 (2023).","DOI":"10.1183\/23120541.00657-2023"},{"key":"74095_CR9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1159\/000067465","volume":"67","author":"M Ferrari","year":"2000","unstructured":"Ferrari, M. et al. Evidence of the rapid protective effect of formoterol dry-powder inhalation against exercise-induced bronchospasm in athletes with asthma. Respiration. 67, 510\u2013513 (2000).","journal-title":"Respiration"},{"key":"74095_CR10","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/j.1476-5381.1993.tb13929.x","volume":"110","author":"AT Nials","year":"1993","unstructured":"Nials, A. T. et al. Effects of beta-adrenoceptor agonists in human bronchial smooth muscle. Br. J. Pharmacol. 110, 1112\u20131116 (1993).","journal-title":"Br. J. Pharmacol."},{"key":"74095_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/eurjpc\/zwab198","volume":"29","author":"PE Adami","year":"2022","unstructured":"Adami, P. E. et al. Cardiovascular effects of doping substances, commonly prescribed medications and ergogenic aids in relation to sports: a position statement of the sport cardiology and exercise nucleus of the European Association of Preventive Cardiology. Eur. J. Prev. Cardiol. 29, 559\u2013575 (2022).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"74095_CR12","unstructured":"Abosamak, N. R. & Shahin, M. H. Beta2 receptor agonists and antagonists. (2024)."},{"key":"74095_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40798-023-00630-3","volume":"9","author":"DA Bizjak","year":"2023","unstructured":"Bizjak, D. A. et al. Acute effects of single Versus Combined inhaled beta2-Agonists salbutamol and formoterol on time trial performance, lung function, metabolic and endocrine variables. Sports Med. Open. 9, 79 (2023).","journal-title":"Sports Med. Open."},{"key":"74095_CR14","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1249\/MSS.0b013e3182951d2d","volume":"45","author":"N Decorte","year":"2013","unstructured":"Decorte, N. et al. Effect of salbutamol on neuromuscular function in endurance athletes. Med. Sci. Sports Exerc. 45, 1925\u20131932 (2013).","journal-title":"Med. Sci. Sports Exerc."},{"key":"74095_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1600-0838.2010.01251.x","volume":"22","author":"J Elers","year":"2012","unstructured":"Elers, J., Morkeberg, J., Jansen, T., Belhage, B. & Backer, V. High-dose inhaled salbutamol has no acute effects on aerobic capacity or oxygen uptake kinetics in healthy trained men. Scand. J. Med. Sci. Sports. 22, 232\u2013239 (2012).","journal-title":"Scand. J. Med. Sci. Sports"},{"key":"74095_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1042\/cs0830615","volume":"83","author":"L Martineau","year":"1992","unstructured":"Martineau, L., Horan, M. A., Rothwell, N. J. & Little, R. A. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin. Sci. (London). 83, 615\u2013621 (1992).","journal-title":"Clin. Sci. (Lond)"},{"key":"74095_CR17","first-page":"131","volume":"5","author":"M Parr","year":"2018","unstructured":"Parr, M. & M\u00fcller-Sch\u00f6ll, A. Pharmacology of doping agents\u2014mechanisms promoting muscle hypertrophy. AIMS Mol. Sci. 5, 131\u2013159 (2018).","journal-title":"AIMS Mol. Sci."},{"key":"74095_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1210\/me.2011-1274","volume":"26","author":"MA Pearen","year":"2012","unstructured":"Pearen, M. A. et al. The nuclear receptor, Nor-1, markedly increases type II oxidative muscle fibers and resistance to fatigue. Mol. Endocrinol. 26, 372\u2013384 (2012).","journal-title":"Mol. Endocrinol."},{"key":"74095_CR19","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1210\/en.2007-1202","volume":"149","author":"MA Pearen","year":"2008","unstructured":"Pearen, M. A. et al. The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. Endocrinology.  149, 2853\u20132865 (2008).","journal-title":"Endocrinology"},{"key":"74095_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/11537540-000000000-00000","volume":"41","author":"BM Pluim","year":"2011","unstructured":"Pluim, B. M. et al. beta(2)-agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials. Sports Med. 41, 39\u201357 (2011).","journal-title":"Sports Med."},{"key":"74095_CR21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1136\/bjsports-2019-100708","volume":"54","author":"A Riiser","year":"2020","unstructured":"Riiser, A., Stensrud, T., Stang, J. & Andersen, L. B. Can beta2-agonists have an ergogenic effect on strength, sprint or power performance? Systematic review and meta-analysis of RCTs. Br. J. Sports Med. 54, 1351\u20131359 (2020).","journal-title":"Br. J. Sports Med."},{"key":"74095_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1136\/bjsports-2019-100984","volume":"55","author":"A Riiser","year":"2021","unstructured":"Riiser, A., Stensrud, T., Stang, J. & Andersen, L. B. Aerobic performance among healthy (non-asthmatic) adults using beta2-agonists: a systematic review and meta-analysis of randomised controlled trials. Br. J. Sports Med. 55, 975\u2013983 (2021).","journal-title":"Br. J. Sports Med."},{"key":"74095_CR23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.bjp.0706669","volume":"147","author":"JG Ryall","year":"2006","unstructured":"Ryall, J. G., Sillence, M. N. & Lynch, G. S. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br. J. Pharmacol. 147, 587\u2013595 (2006).","journal-title":"Br. J. Pharmacol."},{"key":"74095_CR24","unstructured":"World Anti-Doping Agency (WADA), WADA`s Executive Committee. The 2024 prohibited list - world anti-doping code. (2024)."},{"key":"74095_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jfda.2018.12.006","volume":"27","author":"MT Wang","year":"2019","unstructured":"Wang, M. T., Lai, J. H., Tsai, C. L. & Liou, J. T. Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease. J. Food Drug Anal. 27, 657\u2013670 (2019).","journal-title":"J. Food Drug Anal."},{"key":"74095_CR26","doi-asserted-by":"crossref","unstructured":"Janson, C., Wiklund, F., Telg, G., Stratelis, G. & Sandelowsky, H. High use of short-acting beta(2)-agonists in COPD is associated with an increased risk of exacerbations and mortality. ERJ Open Res.9 (2023).","DOI":"10.1183\/23120541.00722-2022"},{"key":"74095_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2147\/COPD.S358927","volume":"17","author":"JE Amegadzie","year":"2022","unstructured":"Amegadzie, J. E., Gamble, J. M., Farrell, J. & Gao, Z. Association between Inhaled beta(2)-agonists initiation and risk of major adverse cardiovascular events: a population-based nested case-control study. Int. J. Chron. Obstruct. Pulmon. Dis. 17, 1205\u20131217 (2022).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"74095_CR28","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2165\/00003495-200565120-00001","volume":"65","author":"M Cazzola","year":"2005","unstructured":"Cazzola, M., Matera, M. G. & Donner, C. F. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs.  65, 1595\u20131610 (2005).","journal-title":"Drugs"},{"key":"74095_CR29","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","volume":"125","author":"SR Salpeter","year":"2004","unstructured":"Salpeter, S. R., Ormiston, T. M. & Salpeter, E. E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest.  125, 2309\u20132321 (2004).","journal-title":"Chest"},{"key":"74095_CR30","doi-asserted-by":"publisher","first-page":"S322","DOI":"10.1067\/mai.2002.129966","volume":"110","author":"MR Sears","year":"2002","unstructured":"Sears, M. R. Adverse effects of beta-agonists. J. Allergy Clin. Immunol. 110, S322\u2013328 (2002).","journal-title":"J. Allergy Clin. Immunol."},{"key":"74095_CR31","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1378\/chest.127.6.2057","volume":"127","author":"EM Kallergis","year":"2005","unstructured":"Kallergis, E. M. et al. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest. 127, 2057\u20132063 (2005).","journal-title":"Chest"},{"key":"74095_CR32","first-page":"203","volume":"43","author":"OE Brodde","year":"1991","unstructured":"Brodde, O. E. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol. Rev. 43, 203\u2013242 (1991).","journal-title":"Pharmacol. Rev."},{"key":"74095_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1161\/01.CIR.94.3.353","volume":"94","author":"GE Newton","year":"1996","unstructured":"Newton, G. E. & Parker, J. D. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 94, 353\u2013358 (1996).","journal-title":"Circulation"},{"key":"74095_CR34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/HJR.0b013e3280ecfe3e","volume":"14","author":"F Furlanello","year":"2007","unstructured":"Furlanello, F., Serdoz, L. V., Cappato, R. & De Ambroggi, L. Illicit drugs and cardiac arrhythmias in athletes. Eur. J. Cardiovasc. Prev. Rehabilit. 14, 487\u2013494 (2007).","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil"},{"key":"74095_CR35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1592\/phco.31.8.748","volume":"31","author":"EM Snyder","year":"2011","unstructured":"Snyder, E. M. et al. Effects of an inhaled beta2-agonist on cardiovascular function and sympathetic activity in healthy subjects. Pharmacotherapy.  31, 748\u2013756 (2011).","journal-title":"Pharmacotherapy"},{"key":"74095_CR36","first-page":"e13672","volume":"13","author":"SA Syed","year":"2021","unstructured":"Syed, S. A. et al. Short-term effect of inhaled salbutamol on heart rate in healthy volunteers. Cureus. 13, e13672 (2021).","journal-title":"Cureus"},{"key":"74095_CR37","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1249\/JSR.0000000000000521","volume":"17","author":"P Simon","year":"2018","unstructured":"Simon, P., Neuberger, E. W., Wang, G. & Pitsiladis, Y. P. Antidoping Science: important lessons from the medical sciences. Curr. Sports Med. Rep. 17, 326\u2013331 (2018).","journal-title":"Curr. Sports Med. Rep."},{"key":"74095_CR38","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/dta.2004","volume":"8","author":"L Martin","year":"2016","unstructured":"Martin, L. et al. New insights for identification of doping with recombinant human erythropoietin micro-doses after high hydration. Drug Test Anal. 8, 1119\u20131130 (2016).","journal-title":"Drug Test. Anal."},{"key":"74095_CR39","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.4155\/bio.12.145","volume":"4","author":"P Schamasch","year":"2012","unstructured":"Schamasch, P. & Rabin, O. Challenges and perspectives in anti-doping testing. Bioanalysis.  4, 1691\u20131701 (2012).","journal-title":"Bioanalysis"},{"key":"74095_CR40","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/sms.12096","volume":"24","author":"A Kalsen","year":"2014","unstructured":"Kalsen, A., Hostrup, M., Bangsbo, J. & Backer, V. Combined inhalation of beta2 -agonists improves swim ergometer sprint performance but not high-intensity swim performance. Scand. J. Med. Sci. Sports.  24, 814\u2013822 (2014).","journal-title":"Scand. J. Med. Sci. Sports"},{"key":"74095_CR41","first-page":"163","volume":"42","author":"W Gaus","year":"1992","unstructured":"Gaus, W. & Hogel, J. Balanced designs for multiple crossover studies. Arzneimittel-Forschung. 42, 163\u2013172 (1992).","journal-title":"Arzneimittel-Forschung"},{"key":"74095_CR42","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1186\/s13063-021-05862-w","volume":"22","author":"M Zugel","year":"2021","unstructured":"Zugel, M. et al. The ELSA trial: single versus combinatory effects of non-prohibited beta-2 agonists on skeletal muscle metabolism, cardio-pulmonary function and endurance performance-study protocol for a randomized 4-way balanced cross-over trial. Trials. 22, 903 (2021).","journal-title":"Trials"},{"key":"74095_CR43","unstructured":"Lang, R. M. et al., Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 28 (1\u201339), e14 (2015)."},{"key":"74095_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jcmg.2014.06.013","volume":"8","author":"K Negishi","year":"2015","unstructured":"Negishi, K. et al. Practical guidance in echocardiographic assessment of global longitudinal strain. JACC Cardiovasc. Imaging. 8, 489\u2013492 (2015).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"74095_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.echo.2014.11.003","volume":"28","author":"JU Voigt","year":"2015","unstructured":"Voigt, J. U. et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI\/ASE\/Industry Task Force to standardize deformation imaging. J. Am. Soc. Echocardiogr. 28, 183\u2013193 (2015).","journal-title":"J. Am. Soc. Echocardiogr"},{"key":"74095_CR46","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/separations10070368","volume":"10","author":"L Harps","year":"2023","unstructured":"Harps, L. et al. Quantitation of formoterol, salbutamol and salbutamol-4\u2019-O-sulfate in human urine and serum by UHPLC-MS\/MS. Separations. 10, 368 (2023).","journal-title":"Separations"},{"key":"74095_CR47","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1093\/eurheartj\/ehy600","volume":"40","author":"C Maack","year":"2019","unstructured":"Maack, C. et al. Treatments targeting inotropy. Eur. Heart J. 40, 3626\u20133644 (2019).","journal-title":"Eur. Heart J."},{"key":"74095_CR48","doi-asserted-by":"crossref","unstructured":"Van Eenoo, P. & Delbeke, F. T. beta-adrenergic stimulation. Handb. Exp. Pharmacol., 227\u2013249 (2010).","DOI":"10.1007\/978-3-540-79088-4_11"},{"key":"74095_CR49","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bcpt.12991","volume":"123","author":"G Milano","year":"2018","unstructured":"Milano, G., Chiappini, S., Mattioli, F., Martelli, A. & Schifano, F. beta-2 agonists as misusing drugs? Assessment of both clenbuterol- and salbutamol-related European medicines agency pharmacovigilance database reports. Basic Clin. Pharmacol. Toxicol. 123, 182\u2013187 (2018).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"74095_CR50","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1177\/0960327110388957","volume":"30","author":"A Boucher","year":"2011","unstructured":"Boucher, A. et al. Salbutamol misuse or abuse with fatal outcome: a case-report. Hum. Exp. Toxicol. 30, 1869\u20131871 (2011).","journal-title":"Hum. Exp. Toxicol."},{"key":"74095_CR51","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/hrt.2008.161638","volume":"95","author":"S Ferrua","year":"2009","unstructured":"Ferrua, S., Varbella, F. & Conte, M. R. Images in cardiology. Acute myocardial infarction due to coronary vasospasm and salbutamol abuse. Heart. 95, 673 (2009).","journal-title":"Heart"},{"key":"74095_CR52","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1136\/bmj.288.6420.824","volume":"288","author":"RJ Winter","year":"1984","unstructured":"Winter, R. J., Langford, J. A. & Rudd, R. M. Effects of oral and inhaled salbutamol and oral pirbuterol on right and left ventricular function in chronic bronchitis. Br. Med. J. (Clin. Res. Ed.). 288, 824\u2013825 (1984).","journal-title":"Br. Med. J. (Clin Res. Ed)"},{"key":"74095_CR53","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S2213-2600(18)30054-7","volume":"6","author":"JM Hohlfeld","year":"2018","unstructured":"Hohlfeld, J. M. et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir. Med. 6, 368\u2013378 (2018).","journal-title":"Lancet Respir Med."},{"key":"74095_CR54","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1113\/JP272037","volume":"594","author":"V Tedjasaputra","year":"2016","unstructured":"Tedjasaputra, V., Bouwsema, M. M. & Stickland, M. K. Effect of aerobic fitness on capillary blood volume and diffusing membrane capacity responses to exercise. J. Physiol. 594, 4359\u20134370 (2016).","journal-title":"J. Physiol."},{"key":"74095_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4137\/CCRPM.S30251","volume":"10","author":"NE Taylor","year":"2016","unstructured":"Taylor, N. E. et al. Albuterol improves alveolar-capillary membrane conductance in healthy humans. Clin. Med. Insights Circ. Respir. Pulm Med. 10, 19\u201325 (2016).","journal-title":"Clin. Med. Insights Circ. Respir Pulm Med."},{"key":"74095_CR56","unstructured":"Lazovic, B. et al. Comparison of lung diffusing capacity in young elite athletes and their counterparts. Rev. Port. Pneumol.  (2006). (2017)."},{"key":"74095_CR57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/PL00007646","volume":"177","author":"ET Iversen","year":"1999","unstructured":"Iversen, E. T., Sorensen, T., Heckscher, T. & Jensen, J. I. Effect of terbutaline on exercise capacity and pulmonary function in patients with chronic obstructive pulmonary disease. Lung. 177, 263\u2013271 (1999).","journal-title":"Lung"},{"key":"74095_CR58","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/0002-9149(84)90036-5","volume":"53","author":"R Erbel","year":"1984","unstructured":"Erbel, R. et al. Effects of heart rate changes on left ventricular volume and ejection fraction: a 2-dimensional echocardiographic study. Am. J. Cardiol. 53, 590\u2013597 (1984).","journal-title":"Am. J. Cardiol."},{"key":"74095_CR59","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/echo.15121","volume":"38","author":"MM Gruca","year":"2021","unstructured":"Gruca, M. M. et al. Strain echocardiography to describe left ventricular function pre- and postexercise in elite basketball athletes: a feasibility study. Echocardiography. 38, 1165\u20131172 (2021).","journal-title":"Echocardiography"},{"key":"74095_CR60","doi-asserted-by":"publisher","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","volume":"9","author":"J Alexandre","year":"2020","unstructured":"Alexandre, J. et al. Cardiovascular toxicity related to cancer treatment: A pragmatic approach to the American and European cardio-oncology guidelines. J. Am. Heart Assoc. 9, e018403 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"74095_CR61","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.mayocp.2018.07.017","volume":"94","author":"SA Luis","year":"2019","unstructured":"Luis, S. A., Chan, J. & Pellikka, P. A. Echocardiographic assessment of left ventricular systolic function: an overview of contemporary techniques, including speckle-tracking echocardiography. Mayo Clin. Proc. 94, 125\u2013138 (2019).","journal-title":"Mayo Clin. Proc."},{"key":"74095_CR62","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon, A. R. et al. ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J. 43, 4229\u20134361 (2022).","journal-title":"Eur. Heart J."},{"key":"74095_CR63","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1161\/CIRCULATIONAHA.106.640334","volume":"115","author":"C Bjork Ingul","year":"2007","unstructured":"Bjork Ingul, C., Rozis, E., Slordahl, S. A. & Marwick, T. H. Incremental value of strain rate imaging to wall motion analysis for prediction of outcome in patients undergoing dobutamine stress echocardiography. Circulation. 115, 1252\u20131259 (2007).","journal-title":"Circulation"},{"key":"74095_CR64","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ahj.2009.09.010","volume":"158","author":"AC Ng","year":"2009","unstructured":"Ng, A. C. et al. Incremental value of 2-dimensional speckle tracking strain imaging to wall motion analysis for detection of coronary artery disease in patients undergoing dobutamine stress echocardiography. Am. Heart J. 158, 836\u2013844 (2009).","journal-title":"Am. Heart J."},{"key":"74095_CR65","doi-asserted-by":"crossref","unstructured":"Bizjak, D., Dreyhaupt, J., Steinacker, J. & Parr, M. Acute effects of single vs. combinatory inhaled \u03b22-agonists salbutamol and formoterol on time trial performance, lung function, metabolic and endocrine variables. (2023).","DOI":"10.1186\/s40798-023-00630-3"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74095-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74095-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74095-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T16:06:17Z","timestamp":1728662777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74095-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74095"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74095-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23437"}}